Investment Research & Advisory Group Inc. Purchases 3,372 Shares of Johnson & Johnson $JNJ

Key Points

• Investment Research & Advisory Group Inc. increased its stake in Johnson & Johnson by 19.3%, acquiring an additional 3,372 shares, bringing its total holdings to 20,866 shares valued at approximately $3.19 million.
• Analysts are optimistic about Johnson & Johnson, with multiple upgrades and a consensus rating of "Moderate Buy," alongside an average price target rise to $181.40.
• The company declared a quarterly dividend of $1.30, resulting in an annualized dividend yield of 2.9% and a payout ratio of 55.61%.

Investment Research & Advisory Group Inc. raised its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 19.3% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 20,866 shares of the company's stock after acquiring an additional 3,372 shares during the period. Johnson & Johnson makes up about 1.2% of Investment Research & Advisory Group Inc.'s holdings, making the stock its 25th largest position. Investment Research & Advisory Group Inc.'s holdings in Johnson & Johnson were worth $3,187,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of JNJ. Apexium Financial LP lifted its stake in shares of Johnson & Johnson by 10.7% in the first quarter. Apexium Financial LP now owns 23,989 shares of the company's stock valued at $3,978,000 after buying an additional 2,310 shares in the last quarter. Avanza Fonder AB boosted its stake in Johnson & Johnson by 2.9% during the 2nd quarter. Avanza Fonder AB now owns 234,647 shares of the company's stock valued at $35,842,000 after purchasing an additional 6,566 shares during the last quarter. Joel Isaacson & Co. LLC increased its holdings in Johnson & Johnson by 3.5% during the 1st quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company's stock worth $12,294,000 after purchasing an additional 2,526 shares in the last quarter. Tokio Marine Asset Management Co. Ltd. raised its stake in shares of Johnson & Johnson by 7.0% in the first quarter. Tokio Marine Asset Management Co. Ltd. now owns 73,350 shares of the company's stock worth $12,164,000 after purchasing an additional 4,816 shares during the last quarter. Finally, Range Financial Group LLC boosted its position in shares of Johnson & Johnson by 18.9% during the first quarter. Range Financial Group LLC now owns 15,886 shares of the company's stock valued at $2,635,000 after buying an additional 2,529 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Guggenheim upgraded Johnson & Johnson from a "neutral" rating to a "buy" rating and raised their price objective for the company from $167.00 to $206.00 in a research note on Tuesday, September 23rd. Wall Street Zen upgraded shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a report on Saturday, September 13th. Citigroup boosted their price target on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a "buy" rating in a report on Thursday, August 21st. Barclays lifted their target price on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 17th. Finally, The Goldman Sachs Group upped their target price on Johnson & Johnson from $185.00 to $186.00 and gave the company a "buy" rating in a report on Friday, September 19th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and nine have given a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $181.40.

Insider Activity at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the firm's stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president directly owned 178,013 shares of the company's stock, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.16% of the company's stock.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $181.63 on Tuesday. The company has a market capitalization of $437.43 billion, a P/E ratio of 19.43, a P/E/G ratio of 2.29 and a beta of 0.40. The business has a fifty day simple moving average of $174.76 and a two-hundred day simple moving average of $162.18. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $181.87.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The company had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. During the same quarter in the prior year, the company earned $2.82 EPS. The firm's quarterly revenue was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were given a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 2.9%. Johnson & Johnson's payout ratio is 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.